Vlado Perkovic's Publications

Predictors of Change in Left-Ventricular Structure and Function in a Trial of Extended Hours Hemodialysis
Journal articles
2020
Journal of Cardiac Failure
The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial.
Journal articles
2020
Diabetes Obes Metab
The impact of COVID-19 pandemic on medical education
Journal articles
2020
Medical Journal of Australia
Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: A secondary analysis of the CREDENCE randomized trial
Journal articles
2020
Journal of the American Society of Nephrology
Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program
Journal articles
2020
Diabetes, Obesity and Metabolism
Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular andor kidney disease: subgroup analysis of the randomized CARMELINAsupsup trial
Journal articles
2020
Diabetology International
CANAGLIFLOZIN (CANA) REDUCES CARDIOVASCULAR (CV) AND RENAL EVENTS INDEPENDENT OF BASELINE HEART FAILURE (HF): A CREDENCE SECONDARY ANALYSIS
Conference Abstracts
2020
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
EFFECTS OF CANAGLIFLOZIN ON STROKE IN THE CREDENCE TRIAL
Conference Abstracts
2020
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL
Conference Abstracts
2020
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
EFFECTS OF SGLT2 INHIBITORS ON STROKE IN TYPE 2 DIABETES ACCORDING TO BASELINE KIDNEY FUNCTION
Conference Posters
2020
Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Journal articles
2020
Journal of the American Heart Association
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial
Journal articles
2020
Circulation
Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes
Journal articles
2020
JACC: Heart Failure
Pilot trials in nephrology: Establishing a base for large-scale randomized trials
Journal articles
2020
Journal of the American Society of Nephrology
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency
Conference Papers
2020
American Journal of Kidney Diseases
Risk of Hospitalization for Heart Failure (HHF) by eGFR and Urinary Albumin-to-Creatinine Ratio (UACR): Pooled Analyses from the CANVAS Program and CREDENCE
Journal articles
2020
Journal of the American Society of Nephrology
Early Change in Albuminuria with Canagliflozin (CANA) Predicts Kidney and Cardiovascular (CV) Outcomes
Journal articles
2020
Journal of the American Society of Nephrology
Hemoglobin A1c Reduction with the GLP-1 Receptor Agonist Semaglutide Is independent of Baseline eGFR: Post Hoc Analysis of SUSTAIN and PIONEER Programs
Journal articles
2020
Journal of the American Society of Nephrology
Effects of Semaglutide on CKD Outcomes: A Post Hoc Pooled Analysis from the SUSTAIN 6 and PIONEER 6 Trials
Journal articles
2020
Journal of the American Society of Nephrology
Reduction in the Rate of eGFR Decline with Semaglutide vs. Placebo: A Post Hoc Pooled Analysis of SUSTAIN 6 and PIONEER 6
Journal articles
2020
Journal of the American Society of Nephrology
Associations Between TNFR-1, TNFR-2, and KIM-1 with Kidney and Cardiovascular Outcomes: Results from the CANVAS Trial
Journal articles
2020
Journal of the American Society of Nephrology
Acute Declines in eGFR During Treatment with Canagliflozin (CANA) and Its Implications for Clinical Practice: Insights from CREDENCE
Journal articles
2020
Journal of the American Society of Nephrology
The SGLT2 Inhibitor Canagliflozin Reduces the Plasma Markers TNFR-1, TNFR-2, and KIM-1 in the CANVAS Trial
Journal articles
2020
Journal of the American Society of Nephrology
Canagliflozin Treatment Reduces Formation and Increases Degradation of Collagen Type III in the Canagliflozin Cardiovascular Assessment Study (CANVAS)
Journal articles
2020
Journal of the American Society of Nephrology
The Effects of Allopurinol on the Progression of CKD According to Baseline Serum Urate Level: Results from Post Hoc Analyses of the CKD-FIX Trial
Journal articles
2020
Journal of the American Society of Nephrology
The Effects of Allopurinol on the Progression of CKD According to Baseline Kidney Function: Prespecified Analyses of the CKD-FIX Trial
Journal articles
2020
Journal of the American Society of Nephrology

Previous Next

Vlado Perkovic's Publications

Predictors of Change in Left-Ventricular Structure and Function in a Trial of Extended Hours Hemodialysis

The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial.

The impact of COVID-19 pandemic on medical education

Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: A secondary analysis of the CREDENCE randomized trial

Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program

Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular andor kidney disease: subgroup analysis of the randomized CARMELINAsupsup trial

CANAGLIFLOZIN (CANA) REDUCES CARDIOVASCULAR (CV) AND RENAL EVENTS INDEPENDENT OF BASELINE HEART FAILURE (HF): A CREDENCE SECONDARY ANALYSIS

EFFECTS OF CANAGLIFLOZIN ON STROKE IN THE CREDENCE TRIAL

EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL

EFFECTS OF SGLT2 INHIBITORS ON STROKE IN TYPE 2 DIABETES ACCORDING TO BASELINE KIDNEY FUNCTION

Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial

Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes

Pilot trials in nephrology: Establishing a base for large-scale randomized trials

Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency

Risk of Hospitalization for Heart Failure (HHF) by eGFR and Urinary Albumin-to-Creatinine Ratio (UACR): Pooled Analyses from the CANVAS Program and CREDENCE

Early Change in Albuminuria with Canagliflozin (CANA) Predicts Kidney and Cardiovascular (CV) Outcomes

Hemoglobin A1c Reduction with the GLP-1 Receptor Agonist Semaglutide Is independent of Baseline eGFR: Post Hoc Analysis of SUSTAIN and PIONEER Programs

Effects of Semaglutide on CKD Outcomes: A Post Hoc Pooled Analysis from the SUSTAIN 6 and PIONEER 6 Trials

Reduction in the Rate of eGFR Decline with Semaglutide vs. Placebo: A Post Hoc Pooled Analysis of SUSTAIN 6 and PIONEER 6

Associations Between TNFR-1, TNFR-2, and KIM-1 with Kidney and Cardiovascular Outcomes: Results from the CANVAS Trial

Acute Declines in eGFR During Treatment with Canagliflozin (CANA) and Its Implications for Clinical Practice: Insights from CREDENCE

The SGLT2 Inhibitor Canagliflozin Reduces the Plasma Markers TNFR-1, TNFR-2, and KIM-1 in the CANVAS Trial

Canagliflozin Treatment Reduces Formation and Increases Degradation of Collagen Type III in the Canagliflozin Cardiovascular Assessment Study (CANVAS)

The Effects of Allopurinol on the Progression of CKD According to Baseline Serum Urate Level: Results from Post Hoc Analyses of the CKD-FIX Trial

The Effects of Allopurinol on the Progression of CKD According to Baseline Kidney Function: Prespecified Analyses of the CKD-FIX Trial

The George Institute for Global Health

The George Institute country sites:

Acknowledgement of Country